Search results
Results from the WOW.Com Content Network
The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end. ... The company's stock slid more than 13% on the news, trading at less than $0.30 per share ...
SHANGHAI (Reuters) - As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators ...
Eli Lilly shares have risen 30% so far this year, and were trading down about 1% at $758.90. Shares of Danish drugmaker Novo Nordisk (NOVOb.CO) have risen 10.6% this year and were trading 3.5% ...
Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a splash in the weight loss space thanks to its one-two punch of blockbuster ...
Lilly's value as a large pharma company isn't only tied to the GLP-1 market. "People think of us as the weight loss company, but actually the rest of the business is really healthy across cancer ...
Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...
In weekly prescription data ending Oct. 18, Eli Lilly's Mounjaro captured 33% of market share, or a year-over-year jump of 79%, while Novo's Ozempic was at 47%, or a year-over-year jump of 39%.
Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro ...